Ambrisentan reduces pulmonary arterial hypertension but does not stimulate alveolar and vascular development in neonatal rats with hyperoxic lung injury

American Journal of Physiology - Lung Cellular and Molecular Physiology

Volumn 304, Issue 4, 2013, Pages

  Wagenaar, Gerry T M ^a   Laghmani, El Houari ^a   de Visser, Yvonne P ^a   Sengers, Rozemarijn M A ^a   Steendijk, Paul ^a   Baelde, Hans J ^a   Walther, Frans J ^a,b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b HARBOR UCLA MEDICAL CENTER   (United States)

Author keywords

Bronchopulmonary dysplasia; Endothelin receptor A antagonist; Nitric oxide synthase inhibition; Pulmonary arterial hypertension; Right ventricular hypertrophy

Indexed keywords

AMBRISENTAN; COLLAGEN TYPE 3; ELASTIN; FIBRIN; MESSENGER RNA; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIAL WALL THICKNESS; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; HEART; HEART RIGHT VENTRICLE PRESSURE; HISTOPATHOLOGY; HYPEROXIA; LUNG; LUNG INJURY; MACROPHAGE; NEUTROPHIL; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; RAT; SURVIVAL; VASCULARIZATION;

ANIMALS; ANIMALS, NEWBORN; HEART; HYPEROXIA; HYPERTENSION, PULMONARY; HYPERTROPHY, RIGHT VENTRICULAR; LUNG; NG-NITROARGININE METHYL ESTER; PHENYLPROPIONATES; PULMONARY ALVEOLI; PYRIDAZINES; RATS; TIME FACTORS;

EID: 84874065398     PISSN: 10400605     EISSN: 15221504     Source Type: Journal    
DOI: 10.1152/ajplung.00073.2012     Document Type: Article

References (50)

1. Abman SH. Recent advances in the pathogenesis and treatment of persistent pulmonary hypertension of the newborn. Neonatology 91: 283-290, 2007.
2. Abman SH. Role of endothelin receptor antagonists in the treatment of pulmonary arterial hypertension. Annu Rev Med 60: 13-23, 2009.
3. Ambalavanan N, Bulger A, Murphy-Ullrich J, Oparil S, Chen YF. Endothelin-A receptor blockade prevents and partially reverses neonatal hypoxic pulmonary vascular remodeling. Pediatr Res 57: 631-636, 2005.
4. Anderson JR, Nawarskas JJ. Pharmacotherapeutic management of pulmonary arterial hypertension. Cardiol Rev 18: 148-162, 2010.
5. Baraldi E, Filippone M. Chronic lung disease after premature birth. N Engl J Med 357: 1946-1955, 2007.
6. Bland RD, Xu L, Ertsey R, Rabinovitch M, Albertine KH, Wynn KA, Kumar VH, Ryan RM, Swartz DD, Csiszar K, Fong KS. Dysregulation of pulmonary elastin synthesis and assembly in preterm lambs with chronic lung disease. Am J Physiol Lung Cell Mol Physiol 292: L1370-L1384, 2007.
7. Chen Y, Hanaoka M, Droma Y, Chen P, Voelkel NF, Kubo K. Endothelin-1 receptor antagonists prevent the development of pulmonary emphysema in rats. Eur Respir J 35: 904-912, 2010.
8. Clozel M, Breu V, Gray GA, Loffler BM. In vivo pharmacology of Ro 46-2005, the first synthetic nonpeptide endothelin receptor antagonist: implications for endothelin physiology. J Cardiovasc Pharmacol 22: S377-S379, 1993.
9. Denault JB, Claing A, D'Orléans-Juste P, Sawamura T, Kido T, Masaki T, Leduc R. Processing of proendothelin-1 by human furin convertase. FEBS Lett 362: 276-280, 1995.
10. de Visser YP, Walther FJ, Laghmani EH, Boersma H, van der Laarse A, Wagenaar GT. Sildenafil attenuates pulmonary inflammation and fibrin deposition, mortality and right ventricular hypertrophy in neonatal hyperoxic lung injury. Respir Res 10: 30, 2009.
11. de Visser YP, Walther FJ, Laghmani EH, van der Laarse A, Wagenaar GT. Apelin attenuates hyperoxic lung and heart injury in neonatal rats. Am J Respir Crit Care Med 182: 1239-1250, 2010.
12. Dupuis J, Goresky CA, Fournier A. Pulmonary clearance of circulating endothelin-1 in dogs in vivo: exclusive role of ETB receptors. J Appl Physiol 81: 1510-1515, 1996.
13. Fonseca C, Abraham D, Renzoni EA. Endothelin in pulmonary fibrosis. Am J Respir Cell Mol Biol 44: 1-10, 2011.
14. Galié N, Manes A, Branzi A. The endothelin system in pulmonary arterial hypertension. Cardiovasc Res 61: 227-37, 2004.
15. Goldie RG, D'Aprile AC, Self GJ, Rigby PJ, Henry PJ. The distribution and density of receptor subtypes for endothelin-1 in peripheral lung of the rat, guinea-pig and pig. Br J Pharmacol 117:729-735, 1996.
16. Habre W, Peták F, Ruchonnet-Metrailler I, Donati Y, Tolsa JF, Lele E, Albu G, Beghetti M, Barazzone-Argiroffo C. The role of endothelin-1 in hyperoxia-induced lung injury in mice. Respir Res 7: 45, 2006.
17. Hirata Y, Emori T, Eguchi S, Kanno K, Imai T, Ohta K, Marumo F. Endothelin receptor subtype B mediates synthesis of nitric oxide by cultured bovine endothelial cells. J Clin Invest 91: 1367-1373, 1993.
18. Hocher B, Schwarz A, Fagan KA, Thöne-Reineke C, El-Hag K, Kusserow H, Elitok S, Bauer C, Neumayer HH, Rodman DM, Theuring F. Pulmonary fibrosis and chronic lung inflammation in ET-1 transgenic mice. Am J Respir Cell Mol Biol 23: 19-26, 2000.
19. Ivy DD, Parker TA, Kinsella JP, Abman SH. Endothelin A receptor blockade decreases pulmonary vascular resistance in premature lambs with hyaline membrane disease. Pediatr Res 44: 175-80, 1998.
20. Ivy D, McMurtry IF, Yanagisawa M, Gariepy CE, Le Cras TD, Gebb SA, Morris KG, Wiseman RC, Abman SH. Endothelin B receptor deficiency potentiates ET-1 and hypoxic pulmonary vasoconstriction. Am J Physiol Lung Cell Mol Physiol 280: L1040-L1048, 2001.
21. Jobe AH, Bancalari E. Bronchopulmonary dysplasia. Am J Respir Crit Care Med 163: 1723-1729, 2001.
22. Jobe AH. The new BPD: an arrest of lung development. Pediatr Res 46: 641-643, 1999.
23. Kinsella JP, Greenough A, Abman SH. Bronchopulmonary dysplasia. Lancet 367: 1421-1431, 2006.
24. Kishi F, Minami K, Okishima N, Murakami M, Mori S, Yano M, Niwa Y, Nakaya Y, Kido H. Novel 31-amino-acid-length endothelins cause constriction of vascular smooth muscle. Biochem Biophys Res Commun 248: 387-390, 1998.
25. Luscher TF, Barton M. Endothelins and endothelin receptor antagonists: therapeutic considerations for a novel class of cardiovascular drugs. Circulation 102: 2434-2440, 2000.
26. Margraf LR, Tomashefski JF Jr, Bruce MC, Dahms BB. Morphometric analysis of the lung in bronchopulmonary dysplasia. Am Rev Respir Dis 143: 391-400, 1991.
27. Mascaretti RS, Mataloun MM, Dolhnikoff M, Rebello CM. Lung morphometry, collagen and elastin content: changes after hyperoxic exposure in preterm rabbits. Clinics (Sao Paulo) 64: 1099-1104, 2009.
28. Michael JR, Markewitz BA. Endothelins and the lung. Am J Respir Crit Care Med 154: 555-581, 1996.
29. Mokres LM, Parai K, Hilgendorff A, Ertsey R, Alvira CM, Rabinovitch M, Bland RD. Prolonged mechanical ventilation with air induces apoptosis and causes failure of alveolar septation and angiogenesis in lungs of newborn mice. Am J Physiol Lung Cell Mol Physiol 298: L23-L35, 2010.
30. Motte S, McEntee K, Naeije R. Endothelin receptor antagonists. Pharmacol Ther 110: 386-414, 2006.
31. Ohlstein EH, Arleth A, Bryan H, Elliott JD, Sung CP. The selective endothelin ETA receptor antagonist BQ123 antagonizes endothelin-1-mediated mitogenesis. Eur J Pharmacol 225: 347-350, 1992.
32. Olave N, Nicola T, Zhang W, Bulger A, James M, Oparil S, Chen YF, Ambalavanan N. Transforming growth factor-regulates endothelin-1 signaling in the newborn mouse lung during hypoxia exposure. Am J Physiol Lung Cell Mol Physiol 302: L857-L865, 2012.
33. Park SH, Saleh D, Giaid A, Michel RP. Increased endothelin-1 in bleomycin-induced pulmonary fibrosis and the effect of an endothelin receptor antagonist. Am J Respir Crit Care Med 156: 600-608, 1997.
34. Pollock DM, Keith TL, Highsmith RF. Endothelin receptors and calcium signaling. FASEB J 9: 1196-1204, 1995.
35. Rozengurt N, Springall DR, Polak JM. Localization of endothelin-like immunoreactivity in airway epithelium of rats and mice. J Pathol 160: 5-8, 1990.
36. Schroll S, Arzt M, Sebah D, Nüchterlein M, Blumberg F, Pfeifer M. Improvement of bleomycin-induced pulmonary hypertension and pulmonary fibrosis by the endothelin receptor antagonist Bosentan. Respir Physiol Neurobiol 170: 32-36, 2010.
37. Seo B, Oemar BS, Siebenmann R, von Segesser L, Luscher TF. Both ETA and ETB receptors mediate contraction to endothelin-1 in human blood vessels. Circulation 89: 1203-1208, 1994.
38. Simon DM, Tsai LW, Ingenito EP, Starcher BC, Mariani TJ. PPARgamma deficiency results in reduced lung elastic recoil and abnormalities in airspace distribution. Respir Res 11: 69, 2010.
39. Soma S, Takahashi H, Muramatsu M, Oka M, Fukuchi Y. Localization and distribution of endothelin receptor subtypes in pulmonary vasculature of normal and hypoxia-exposed rats. Am J Respir Cell Mol Biol 20: 620-630, 1999.
40. Steinhorn RH. Neonatal pulmonary hypertension. Pediatr Crit Care Med 11: S79-S84, 2010.
41. Thibeault DW, Mabry SM, Ekekezie II, Truog WE. Lung elastic tissue maturation and perturbations during the evolution of chronic lung disease. Pediatrics 106: 1452-1459, 2000.
42. Tuder RM, Abman SH, Braun T, Capron F, Stevens T, Thistlethwaite PA, Haworth SG. Development and pathology of pulmonary hypertension. J Am Coll Cardiol 54: S3-S9, 2009.
43. Uhlmann D, Gaebel G, Armann B, Ludwig S, Hess J, Pietsch U, Fiedler M, Tannapfel A, Hauss J, Witzigmann H. Attenuation of proinflammatory gene expression and microcirculatory disturbances by endothelinA receptor blockade after orthotopic liver transplantation in pigs. Surgery 139: 61-72, 2006.
44. Umar S, de Visser YP, Steendijk P, Schutte CI, Laghmani EH, Wagenaar GT, Bax WH, Mantikou E, Pijnappels DA, Atsma DE, Schalij MJ, van der Wall EE, van der Laarse A. Allogenic stem cell therapy improves right ventricular function by improving lung pathology in rats with pulmonary hypertension. Am J Physiol Heart Circ Physiol 297: H1606-H1616, 2009.
45. Valdenaire O, Lepailleur-Enouf D, Egidy G, Thouard A, Barret A, Vranckx R, Tougard C, Michel JB. A fourth isoform of endothelinconverting enzyme (ECE-1) is generated from an additional promoter: molecular cloning and characterization. Eur J Biochem 264: 341-349, 1999.
46. Wagenaar GT, ter Horst SA, van Gastelen MA, Leijser LM, Mauad T, van der Velden PA, de Heer E, Hiemstra PS, Poorthuis BJ, Walther FJ. Gene expression profile and histopathology of experimental bronchopulmonary dysplasia induced by prolonged oxidative stress. Free Radic Biol Med 36: 782-801, 2004.
47. Wagenaar GT, de Visser YP, Laghmani EH, Walther FJ. Ambrisentan prolongs survival by attenuating pulmonary hypertension, fibrin deposition and right ventricular hypertrophy in neonatal hyperoxic lung injury. Am J Respir Crit Care Med 183: A3941, 2011.
48. Wendel DP, Taylor DG, Albertine KH, Keating MT, Li DY. Impaired distal airway development in mice lacking elastin. Am J Respir Cell Mol Biol 23: 320-326, 2000.
49. Yi M, Jankov RP, Belcastro R, Humes D, Copland I, Shek S, Sweezey NB, Post M, Albertine KH, Auten RL, Tanswell AK. Opposing effects of 60% oxygen and neutrophil influx on alveologenesis in the neonatal rat. Am J Respir Crit Care Med 170: 1188-1196, 2004.
50. Yuyama H, Fujimori A, Sanagi M, Koakutsu A, Sudoh K, Sasamata M, Miyata K. The orally active nonpeptide selective endothelin ETA receptor antagonist YM598 prevents and reverses the development of pulmonary hypertension in monocrotaline-treated rats. Eur J Pharmacol 496: 129-139, 2004.